Odyssey Health signs exclusive worldwide sub-license for BreastCheck non-invasive breast test

Odyssey Health, Inc.

Sub-license grants exclusive global marketing and distribution rights for BreastCheck, a 15-minute at-home test.
BreastCheck is FDA registered in the US and registered in EU and UK; targets $26B breast cancer diagnostics market.
Deal managed through subsidiary Odyssey Medical Devices; subject to closing conditions.
CEO expects near-term commercialization and initial revenue, marking transition from development-stage to revenue-generating.
No financial terms (upfront fee, milestones, royalties) disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.